TUESDAY, MAY 18
Arrival and Registration

WEDNESDAY, MAY 19
Stem Cells and Cancer
Duanqing Pei†, Guangzhou Institutes of Biomedicine and Health, China
Chemical Induction of Pluriptotency
Markus Grompe, Oregon Health & Science University, USA
The Role of Polyploid Hepatocytes during Liver Regeneration and Cancer
Lola McAdams Reid, University of North Carolina at Chapel Hill, USA
Patch Grafting of Endodermal Stem/Progenitor Organoids Enable Hepatic and Pancreatic Cell Therapies
Short Talks Chosen from Abstracts

Cancer Stem Cells, Tumor Microenvironment and Immunity
Jos J. Melenhorst, University of Pennsylvania, USA
Remission and Relapse in Chimeric Antigen Receptor Reprogrammed T Cell Therapies
Calvin Kuo, Stanford University, USA
Organoid Modeling of the Tumor Microenvironment
Justin D. Lathia, Cleveland Clinic, USA
Targeting Cancer Stem Cell Immune Cell Interactions in Glioblastoma
Erwei Song, Sun-Yat-Sen Memorial Hospital, China
Tumor Microenvironment and Cancer Stem Cells
Short Talks Chosen from Abstracts

Cancer Stem Cells, Tumor Microenvironment and Immunity
Lijian Hui, Shanghai Institutes of Biological Sciences, China
Talk Title to be Announced
Klaus H. Kaestner, University of Pennsylvania School of Medicine, USA
Genetic Screens for Drivers and Modifiers of Liver Cancer
Short Talks Chosen from Abstracts

Poster Session 2
FRIDAY, MAY 21
Cancer Stem Cells: Modeling and Regulation
Clemens A. Schmitt, Max Delbrück Center for Molecular Medicine, Germany
Senescence Associated Stemness as a Mechanism of Treatment Failure in Cancer
Wei Guo, University of Pennsylvania, USA
Tumor-Derived Exosomes in Immune Suppression
Carmen Chak-Lui Wong, University of Hong Kong, Hong Kong
miRNAs and Hepatic Cancer Stem Cells
Short Talks Chosen from Abstracts

Cancer Stem Cells: Clinical Translation
Dean G. Tang, Roswell Park Cancer Institute, USA
Molecular Understanding and Therapeutic Targeting of Prostate Cancer Cell Heterogeneity
Anna Dubrovska†, University Hospital Carl Gustav Carus, Germany
Cancer Stem Cells as Biomarkers for Radiotherapy Outcome and Targets for Combined Treatments
Chunzhang Yang, NCI, National Institutes of Health, USA
IDH1 Mutation Predisposes Distinctive Therapeutic Vulnerabilities in Glioma Stem Cells
Wolf Ruprecht Wiedemeyer†, Abbvie, USA
Characterization and Targeting of Distinct Subpopulations Driving Tumor Progression and Drug Resistance in Advanced Solid Tumors
Short Talks Chosen from Abstracts

Closing Keynote Address
Irving L. Weissman, Stanford University, USA
Normal and Neoplastic Stem Cells

Meeting Wrap-Up: Outcomes and Future Directions (Organizers)
SATURDAY, MAY 22
Departure

* Session Chair † Invited but not yet accepted     Program current as of May 2, 2020. Program subject to change. Meal formats are based on meeting venue. For the most up-to-date details, visit https://www.keystonesymposia.org.